Kymab
UK-based monoclonal antibody discovery firm, Kymab, has named Christian Groendahl (left) - ex CSO of Zealand Pharma, as well as working for Novo Nordisk - as CEO.
“Kymab has developed a world class human antibody discovery platform since its formation in 2009,” said founder Dr. Allan Bradley, and “Christian’s unique mix of skills and experience will be invaluable in taking the company to the next level.”
The firm also has a new Chairman in the guise of Dr David Chiswell (right), who is currently non-executive Director of Kymab.